Bluejay Diagnostics
BJDX
4 hedge funds and large institutions have $47.8K invested in Bluejay Diagnostics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
104% more capital inflows, than outflows
Capital inflows: $27.1K | Capital outflows: $13.3K
100% more funds holding
Funds holding: 2 → 4 (+2)
0.21% more ownership
Funds ownership: 0.67% → 0.87% (+0.21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRT Financial
New York
|
+$9.04K |
| 2 |
Renaissance Technologies
New York
|
+$9.04K |
| 3 |
Two Sigma Securities
New York
|
+$9.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$5.01K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.28K |
| 3 |
Virtu Financial
New York
|
-$4K |
BJDX Hedge Fund Activity: Q2 2023 in Review
4 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Bluejay Diagnostics (BJDX) for Q2 2023, worth a combined $47.8K — down 14% from $55.7K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BJDX positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $9.04K. The largest seller was Jane Street, cutting an estimated $5.01K.
- 4 institutional investors held Bluejay Diagnostics (BJDX) as of Q2 2023, up from 2 in Q1 2023.
- Funds reported $47.8K of Bluejay Diagnostics stock for Q2 2023, down 14% quarter-over-quarter.
- 2 funds opened new Bluejay Diagnostics positions in Q2 2023 and 0 closed out, a net change of +2 holders.
- The largest Bluejay Diagnostics buyer in Q2 2023 was HRT Financial, an estimated $9.04K added.
- The largest Bluejay Diagnostics seller in Q2 2023 was Jane Street, an estimated $5.01K sold.
Based on aggregated 13F filings for Q2 2023.